Skip to content
Search AI Powered

Latest Stories

A New Dawn for NYC Cannabis Businesses As Gov. Hochul Provides Tax Relief

New York’s governor, Kathy Hochul, signed groundbreaking legislation providing much-needed tax relief to New York City marijuana businesses, a significant move in a landscape where federal deductions under Internal Revenue Service (IRS) code 280E are currently off-limits.

NY's Cannabis Industry Gets Some Tax Relief Thanks to Gov. Hochul
NY's Cannabis Industry Gets Some Tax Relief Thanks to Gov. Hochul

New York’s governor, Kathy Hochul, has recently signed groundbreaking legislation providing much-needed tax relief to New York City marijuana businesses, a significant move in a landscape where federal deductions under Internal Revenue Service (IRS) code 280E are currently off-limits. This decisive action comes after a five-month wait following the Senate and Assembly’s approval of the proposal, underscoring the state’s commitment to supporting the burgeoning cannabis industry, according to Marijuana Moment.

The legislation represents a pivotal step in addressing the unique tax challenges faced by cannabis businesses. Historically, these entities have been hamstrung by federal policies that severely limit their ability to make standard business deductions. The new law seeks to bridge this gap at the city level, following a similar state-level initiative included in last year's separate budget bill. However, New York City’s distinct tax laws remained unaffected by the earlier state-level change, necessitating this targeted intervention.


Specifically, the new measure allows cannabis businesses to deduct expenses related to the sale, distribution, or production of adult-use cannabis products or medical cannabis for the unincorporated business tax (UBT), the general corporation tax (GCT), and the corporate tax of 2015, commonly referred to as the business corporation tax (BCT). This change aligns the city’s tax policies more closely with New York State law, which recognizes and supports these businesses akin to any other legitimate enterprise.

In practical terms, the city’s tax code will be amended to permit deductions equivalent to those denied under section 280E of the federal internal revenue code. This adjustment acknowledges the unique status of cannabis-related businesses, which, while unable to claim federal tax deductions, are nonetheless legal and encouraged under New York law. The bill’s memo highlights this rationale, emphasizing the need for city business taxes to foster these activities.

This legislative reform, backed by New York City Mayor Eric Adams, reflects a broader trend across various states. As federal marijuana reform continues to stall in Congress, leaving state-licensed cannabis businesses facing disproportionately high federal tax rates, states are stepping up. New York joins the ranks of Pennsylvania, Maine, Illinois, Connecticut, and New Jersey, all of which have recently enacted similar measures to provide state-level tax relief to cannabis businesses. These initiatives represent a patchwork of solutions to a federal problem, with states increasingly acting independently to support their legal cannabis industries.

In May, Rep. Earl Blumenauer (D-OR) reintroduced a bill aimed at amending the IRS code, a move that would enable state-legal marijuana businesses to take federal tax deductions like those available to other industries. Blumenauer's efforts highlight the growing recognition of the incongruities in current tax laws and the need for federal action. However, until such federal reforms are enacted, the cannabis industry continues to navigate a complex and often contradictory tax landscape.

The IRS has offered limited guidance on the application of Section 280E, a gap that was somewhat addressed in a 2020 update. This update clarified that cannabis businesses, while restricted from standard deductions, can reduce their gross receipts by properly calculated costs of goods sold to determine gross income. This guidance came in response to a Treasury Department internal watchdog report criticizing the IRS for insufficiently advising marijuana industry taxpayers about compliance with federal tax laws.

An overarching resolution to the industry’s 280E problem could emerge if the Drug Enforcement Administration (DEA) heeds the recommendation of the U.S. Department of Health and Human Services (HHS) to reclassify marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). Such a reclassification would not only address tax issues but also herald a significant shift in the federal government's stance on cannabis.

In conclusion, New York City's recent legislation marks a vital step in addressing the disproportionate tax burden on cannabis businesses. It reflects a growing awareness and acceptance of the cannabis industry's legitimacy and the need for equitable tax treatment.

As states like New York take the lead, the pressure mounts on the federal government to enact comprehensive reforms, harmonizing tax laws with the evolving landscape of cannabis legalization and commerce.

More For You

map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report byThe New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy
Transparency in NY's Cannabis Market: The NYMCIA Controversy

Selective Outrage Hurts NY Cannabis

Authored by: Veterans Holdings CEO Jason Ambrosino

Last week, the New York Medical Cannabis Industry Association (NYMCIA) issued a press release accusing licensed dispensaries of selling "out-of-state cannabis" and undermining the integrity of the legal market. Read the press release here.

Keep ReadingShow less
image of a circle of doctors and surgeons standing over and looking at a patient on operating room table
New Study Confirms Medical Cannabis Benefits in Cancer Care—Time for Policy to Catch Up
Photo by National Cancer Institute on Unsplash

Cannabis & Cancer: The Evidence Is In—So Why Is the Medical Establishment Still Dragging Its Feet?

If you've ever watched a loved one battle cancer—or been on that journey yourself—you already know the harsh truth: the pain is real, the nausea is relentless, the appetite is gone, and the side effects of treatment often feel worse than the disease. So when patients say cannabis helps, it shouldn’t take 10,000 studies for the medical community to take them seriously.

And yet, here we are.

Keep ReadingShow less
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Cannabis and Aging: A Groundbreaking Study Challenges Long-Held Beliefs - The Bluntness
Giphy

Aging & Cannabis: New Findings

For decades, cannabis has been widely regarded as a substance with potential cognitive risks, particularly when used over long periods. Governments across the globe have classified it as a controlled substance, citing concerns about the effects of marijuana use, including memory loss, diminished executive function, and long-term neurological impact. But new research is challenging this long-standing assumption, suggesting that cannabis use may not be linked to age-related cognitive decline—and might even be associated with better cognitive preservation over time.

A recent study published in PubMed (NIH, 2024) followed over 5,000 men for more than four decades to analyze the long-term cognitive effects of cannabis use. The results? Men with a history of cannabis use experienced less cognitive decline from early adulthood to late midlife compared to those who never used cannabis.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less